+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Age: 18Years +
All Genders
ID07101094

Real-World Registry Evaluating Treatment Satisfaction and Use of Xanomeline and Trospium Chloride in Adults with Schizophrenia

Led by Bristol-Myers Squibb · Updated on 2026-09-30

300

Participants Needed

20

Research Sites

14 weeks

Total Duration

AI-Summary

What This Trial Is About

This study focuses on adults in the United States with schizophrenia who are prescribed xanomeline and trospium chloride XT therapy. It aims to understand patients treatment preferences and satisfaction with this medication combination. The research is observational and tracks real-world experiences rather than testing new treatments. Participants receive xanomeline and trospium chloride therapy according to the product label. The study observes how patients use this treatment and collects information about dosing and any changes over time. Data is gathered at multiple points, including baseline, Month 1, Month 3, and Month 6, to monitor treatment plans and medication adjustments. During the study, participants provide information through questionnaires about their medication preferences and satisfaction. Researchers also collect clinical and demographic data, track treatment plans, dose changes, and reasons for discontinuing therapy. This information helps assess the real-world use and patient experience with XT therapy over approximately six months.

CONDITIONS

Brief Title

Evaluation of Treatment Satisfaction and KarXT Utilization Registry (RESKU)

Research Team

B

BMS Clinical Trials Contact Center www.BMSClinicalTrials.com

F

First line of the email MUST contain NCT # and Site #.

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here